I am a
Home I AM A Search Login

Papers of the Week

Papers: 11 May 2024 - 17 May 2024

2024 May 13

J Eur Acad Dermatol Venereol


EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions.


Ständer S, Pereira MP, Zeidler C, Legat FJ, Misery L, Lönndahl L, Bewley AP, Brenaut E, Bobko S, Elberling J, Evers AWM, Garcovich S, Gieler U, Gonçalo M, Kupfer J, Lambert J, Lvov A, Metz M, Michenko A, Papadavid E, Reich A, Savk E, Schneider G, Schut C, Serra-Baldrich E, Ständer HF, Szepietowski JC, Wallengren J, Weisshaar E, Augustin M


Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the future due to the ageing population. The clinical presentation, underlying aetiology and treatment strategy of CP are heterogeneous. Also, individual treatment aims and physical, psychic and economic burdens of patients might vary. Chronic prurigo (CPG) is the most severe disease in the chronic pruritus spectrum, being associated with long-standing scratch-induced skin lesions and a therapy refractory itch-scratch-cycle. It is thus important to raise disease awareness for CP and CPG in the general public and among decision-makers in the health system. Further, there is a need to support a rational clinical framework to optimize both diagnostics and therapeutics. Currently, there is still a shortcoming regarding approved therapies and understanding CP/CPG as severe medical conditions. Therefore, the EADV Task Force Pruritus decided to publish this white paper based on several consensus meetings. The group consented on the following goals: (a) ensure that CP is recognized as a serious condition, (b) increase public awareness and understanding of CP and CPG as chronic and burdensome diseases that can greatly affect a person’s quality of life, (c) clarify that in most cases CP and CPG are non-communicable and not caused by a psychiatric disease, (d) improve the support and treatment given to patients with CP to help them manage their disease and (e) publicize existing therapies including current guidelines. We aim to point to necessary improvements in access and quality of care directed to decision-makers in health policy, among payers and administrations as well as in practical care.